Furosemide controlled release - scPharmaceuticals

Drug Profile

Furosemide controlled release - scPharmaceuticals

Alternative Names: Furoscix; Furosemide micropump patch - scPharmaceuticals/Sensile Medical; SCP-101

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator scPharmaceuticals
  • Developer Johns Hopkins University; scPharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Loop diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase II/III Decompensated heart failure
  • Phase II Heart failure

Most Recent Events

  • 20 Sep 2016 Pharmacodynamics data from a phase II/III trial in Decompensated heart failure released by scPharmaceuticals
  • 22 Jun 2016 scPharmaceuticals plans a phase III trial for Chronic heart failure in USA (SC) (NCT02804282)
  • 01 May 2016 scPharmaceuticals initiates enrolment in a phase I/II trial for Decompensated heart failure in USA (NCT02721511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top